Cagrilintide — Long-acting amylin analog (amylin receptor agonist)

The rationale for cagrilintide is mechanistic complementarity with GLP-1 agonists: amylin receptors are in the area postrema and hypothalamus (different circuits from GLP-1's arcuate nucleus pathway), enabling additive appetite suppression without receptor saturation. REDEFINE 1 Phase 3 trial (CagriSema 2.4/2.4mg): interim data showed ~22% weight loss — comparable to tirzepatide 15mg. Monotherapy cagrilintide produces modest weight loss (~8%), but the combination with semaglutide demonstrates synergism. Amylin analog safety is well-established via pramlintide (Symlin, FDA-approved since 2005), reducing new mechanism-related risk concerns.

نظرة عامة

هذه الصفحة جزء من مكتبة المركّبات المُصنَّفة بالأدلة في Hormonaly. جميع الادعاءات السريرية مرتبطة بمصادر علمية مُحكَّمة عبر خط أنابيب التحقق المزدوج للاستشهادات.

فئة المركّب

Long-acting amylin analog (amylin receptor agonist)

آلية العمل

Cagrilintide is a fatty acid-acylated analog of human amylin (islet amyloid polypeptide, IAPP), co-secreted with insulin from pancreatic β-cells. Amylin receptor activation acts via a distinct, complementary mechanism to GLP-1: activates area postrema (brainstem satiety center) independently of GLP-1 receptors, slows gastric emptying more potently than GLP-1 agonists, suppresses postprandial glucagon, reduces food intake through central circuits different from hypothalamic GLP-1 pathways. Critically, amylin and GLP-1 receptors are located in different brain regions — combining both (CagriSema) produces additive rather than redundant suppression of appetite. Long-acting formulation (half-life ~8 days) achieved via fatty acid acylation enabling albumin binding, analogous to semaglutide's design.

الوضع التنظيمي

Investigational — Phase 3 REDEFINE trials ongoing; CagriSema FDA submission anticipated 2025-2026

مستوى الأدلة

Moderate-High — Phase 3 REDEFINE program ongoing; Phase 2 monotherapy +8% weight loss, CagriSema +16% at interim